Pre-clinical intelligence plays an important role in understanding toxicology during drug development
Biotechnology and pharmaceutical companies rely on toxicity testing to ensure the safety of their products for human use. Unanticipated preclinical toxicity and adverse events in the clinical stage are leading causes of drug attrition, directly contributing to the rapidly increasing costs of drug development. It is estimated that for every eight active substances entering Phase I clinical trials, only one product is approved and marketed. To improve success rates, each step in the drug discovery phase and the use of best practices throughout the workflow are crucial, and the use of big data and artificial intelligence facilitates accurate predictions.
Download the executive summary now, then contact us to learn how Cortellis can help you improve your toxicology processes.